Also known as: ICI
New research links gut microbiome composition to cancer immunotherapy outcomes. A 674-patient study showed gut bacteria predict melanoma recurrence with up to 94% accuracy, while other studies identified specific microbes influencing treatment response and resistance in melanoma and liver cancer.
Meta-analysis of 24 trials found chemoimmunotherapy improved survival in PD-L1-high advanced NSCLC. PPIs and antibiotics were linked to worse durvalumab outcomes, and a chronotherapy trial was retracted.
Candel initiated the Phase 3 AURORA trial of aglatimagene in NSCLC and plans a Q4 2026 BLA in localized prostate cancer, with a potential 2027 launch. The company also appointed a Chief Commercial Officer.
A deep learning pathomics platform called Path-IO accurately predicted outcomes and immunotherapy response in NSCLC patients using routine pathology slides, outperforming the PD-L1 biomarker. The model was validated across multiple cohorts and improved further when combined with radiomics and clinical data. If validated, it could be easily integrated into clinical workflows.
ASCO 2026 data show CBM588 boosts immunotherapy in kidney cancer and a bispecific combo improves lymphoma. Early-day ICI infusion, mezigdomide T cell reinvigoration, and dostarlimab maintenance also advance cancer immunotherapy.
The International Cardio-Oncology Society has released new guidelines for managing cancer therapy-related cardiac dysfunction, addressing educational gaps identified in a survey of 220 healthcare providers. The survey found highest educational needs for topics like immune checkpoint inhibitor-associated myocarditis and atrial fibrillation management.
A 12-week supervised remote exercise program for patients with metastatic renal cell carcinoma undergoing immunotherapy showed significant improvements in health-related quality of life, fatigue, and symptom burden in a case series of 19 patients.
A Phase 1b/2 trial in 28 patients found nivolumab plus modified FOLFIRINOX was well tolerated before surgery in borderline-resectable pancreatic cancer. Seventy-nine percent proceeded to surgery, with complete tumor removal in all resected patients.
A study in stage 3 dMMR colon cancer found that atezolizumab plus chemotherapy after surgery cut recurrence and death risk by 50%. The trial enrolled 712 patients and the regimen is now included in treatment guidelines.
Studies on immune checkpoint inhibitor therapy found pretreatment biomarkers strongly predicted checkpoint inhibitor-associated autoimmune diabetes, while hyperglycemia during treatment was common and did not worsen disease progression.
